Best Peptides for Fat Loss 2026: Evidence-Ranked Guide
The peptide landscape for fat loss has expanded dramatically since the GLP-1 revolution began. But "best" depends entirely on what you're optimizing for: clinical evidence, magnitude of weight loss,…
The peptide landscape for fat loss has expanded dramatically since the GLP-1 revolution began. But "best" depends entirely on what you're optimizing for: clinical evidence, magnitude of weight loss, side effect profile, legal accessibility, or cost. This ranking evaluates every peptide with a plausible fat-loss mechanism, ordered by strength of evidence — because what works in a controlled clinical trial matters more than what's popular on Reddit.
Our Ranking Methodology
We rank peptides for fat loss across four dimensions:
- Evidence strength — FDA-approved with Phase 3 data ranks highest, followed by human trials, animal studies, and theoretical mechanisms
- Magnitude of effect — How much weight loss does the evidence actually support?
- Safety profile — Documented risks at effective doses
- Accessibility — Can you actually get it legally and affordably?
Tier 1: FDA-Approved (Strongest Evidence)
1. Tirzepatide (Mounjaro/Zepbound)
The current gold standard for peptide-based fat loss.
Tirzepatide is a dual GIP/GLP-1 receptor agonist that has produced the most impressive weight loss results of any pharmaceutical intervention short of bariatric surgery. The SURMOUNT-1 trial demonstrated average weight loss of 20.9% at the 15mg dose over 72 weeks — that's roughly 48 pounds for a 230-pound person.
- Evidence grade: FDA-APPROVED
- Average weight loss: 15-21% of body weight (dose-dependent)
- Key trials: SURMOUNT-1/2/3/4, SURPASS series
- Administration: Weekly subcutaneous injection
- Major side effects: GI effects (nausea, vomiting, diarrhea), thyroid C-cell tumor warning (black box)
- Price range: $249-$549/month (compounded), $1,000+/month (brand-name)
- Vendor data: 136 vendors tested, 1,748 samples
Read our full tirzepatide profile | Compare tirzepatide vs semaglutide
2. Semaglutide (Ozempic/Wegovy)
The peptide that started the GLP-1 weight loss revolution.
Semaglutide 2.4mg (Wegovy) was the first GLP-1 agonist specifically approved for chronic weight management. The STEP 1 trial showed 14.9% average weight loss over 68 weeks. The SELECT cardiovascular outcomes trial additionally demonstrated a 20% reduction in major adverse cardiovascular events — making semaglutide the first weight loss drug to show cardiovascular benefit.
- Evidence grade: FDA-APPROVED
- Average weight loss: 12-15% of body weight
- Key trials: STEP 1-5, SELECT
- Administration: Weekly subcutaneous injection (or daily oral as Rybelsus)
- Major side effects: GI effects, pancreatitis risk, thyroid warning
- Price range: $199-$399/month (compounded), $1,300+/month (brand-name)
- Vendor data: 84 vendors tested, 920 samples
Read our full semaglutide profile | Compare wegovy vs ozempic
3. Tesamorelin (Egrifta)
FDA-approved specifically for reducing visceral fat — the dangerous kind.
Tesamorelin is a growth hormone-releasing hormone (GHRH) analog approved for HIV-associated lipodystrophy. It specifically targets visceral adipose tissue (VAT) — the metabolically active fat surrounding organs that drives insulin resistance and cardiovascular risk. Unlike GLP-1 agonists, tesamorelin doesn't primarily work through appetite suppression; it increases growth hormone, which preferentially mobilizes visceral fat.
- Evidence grade: FDA-APPROVED
- Target: Visceral fat reduction (not total body weight)
- Average VAT reduction: 15-18% over 26 weeks
- Administration: Daily subcutaneous injection
- Major side effects: Joint pain, fluid retention, glucose elevation
- Vendor data: 29 vendors tested, 156 samples
Read our full tesamorelin profile
4. Liraglutide (Saxenda)
The first-generation GLP-1 that paved the way.
Liraglutide 3.0mg (Saxenda) was the first GLP-1 agonist approved for weight management. It produces less weight loss than semaglutide or tirzepatide (average 8% vs 15-21%), but it has the longest post-market safety track record and is being displaced by newer agents. Still relevant for patients who can't tolerate weekly injectables — liraglutide is a daily injection.
- Evidence grade: FDA-APPROVED
- Average weight loss: 5-8% of body weight
- Key trials: SCALE
- Administration: Daily subcutaneous injection
Read our full liraglutide profile | Compare liraglutide vs semaglutide
Tier 2: Human Trials (Strong Emerging Evidence)
5. Retatrutide
The triple agonist that could surpass tirzepatide.
Retatrutide activates three receptors — GIP, GLP-1, and glucagon — compared to tirzepatide's two. Phase 2 data showed up to 24.2% weight loss at the highest dose over 48 weeks. If Phase 3 confirms this, retatrutide would be the most effective weight loss peptide ever studied. It also showed dramatic reductions in liver fat (82-86%), making it promising for MASLD/MASH.
- Evidence grade: HUMAN TRIALS (Phase 3 ongoing)
- Average weight loss: Up to 24.2% (Phase 2)
- Vendor data: 48 vendors tested, 312 samples
Read our full retatrutide profile | Compare retatrutide vs tirzepatide
6. Orforglipron
The oral GLP-1 that could eliminate needles.
Orforglipron is not a peptide — it's a small-molecule GLP-1 agonist that can be taken as a daily pill. Phase 2 data showed 14.7% weight loss at 36 weeks. If Phase 3 succeeds and it's approved, it would be the first effective oral weight loss treatment in this class, dramatically expanding access beyond the injection-only options.
- Evidence grade: HUMAN TRIALS (Phase 3 ongoing)
- Average weight loss: 9-15% (Phase 2, dose-dependent)
Read our full orforglipron profile
7. CJC-1295 + Ipamorelin Stack
The GH secretagogue approach to body recomposition.
This combination stimulates natural growth hormone release, which preferentially mobilizes fat while preserving lean mass. It doesn't produce the dramatic scale-weight changes of GLP-1 agonists, but proponents argue the body composition changes (fat loss + muscle preservation) are more favorable. The evidence is from small human studies, not large randomized trials.
- Evidence grade: HUMAN TRIALS (small studies)
- Mechanism: GH-mediated fat mobilization
- Vendor data: CJC-1295: 47 vendors/245 samples; Ipamorelin: 41 vendors/261 samples
Read CJC-1295 profile | Read Ipamorelin profile
Tier 3: Animal Studies (Experimental)
8. AOD-9604
A fragment of human growth hormone (hGH 177-191) that was specifically designed to have fat-loss effects without the metabolic side effects of full GH. Phase 2 human trials showed modest weight loss, but the results were not impressive enough to proceed to Phase 3. Currently sold as a research peptide.
9. 5-Amino-1MQ
An NNMT (nicotinamide N-methyltransferase) inhibitor that has shown fat-reduction effects in animal models. The mechanism is novel — inhibiting NNMT shifts cellular metabolism toward fat oxidation. No human clinical trials completed. Entirely experimental.
The Bottom Line
If you're looking for the most evidence-supported approach to peptide-based fat loss, the ranking is clear: tirzepatide and semaglutide are in a different league from everything else. They're FDA-approved, supported by trials involving tens of thousands of patients, and produce weight loss that was previously only achievable through surgery.
Everything below Tier 1 requires progressively more tolerance for uncertainty. Retatrutide looks incredibly promising but needs Phase 3 confirmation. GH secretagogues offer a different approach but with weaker evidence for fat loss specifically. And animal-study peptides like AOD-9604 and 5-Amino-1MQ are speculative bets at this stage.
The right peptide for fat loss depends on your risk tolerance, budget, access to medical supervision, and whether you want a proven pharmaceutical or are willing to explore experimental options. Use our peptide quiz to get a personalized recommendation based on your specific profile.
Frequently Asked Questions
What is the most effective peptide for fat loss?
Based on clinical trial data, tirzepatide (Mounjaro/Zepbound) produces the most weight loss at 15-21% of body weight on average. Semaglutide (Wegovy) follows at 12-15%. These are the only peptides with large-scale Phase 3 trial data specifically for weight management.
Are fat loss peptides safe?
FDA-approved options (tirzepatide, semaglutide, liraglutide, tesamorelin) have documented safety profiles from clinical trials. Common side effects include GI symptoms and injection site reactions. Both tirzepatide and semaglutide carry black box warnings for thyroid C-cell tumors. Research-only peptides lack comprehensive human safety data.
How much do fat loss peptides cost?
Compounded semaglutide: $199-399/month. Compounded tirzepatide: $249-549/month. Brand-name versions: $1,000+/month. GH secretagogues: $100-300/month from research vendors. Costs vary significantly by vendor and dosing protocol.
Can I use peptides for fat loss without a prescription?
GLP-1 agonists (semaglutide, tirzepatide) require a prescription. Research peptides like CJC-1295, ipamorelin, and AOD-9604 are sold as research chemicals and exist in a legal gray area. See our guide on peptide legality for details.
Do peptides for fat loss cause muscle loss?
GLP-1 agonists can cause lean mass loss along with fat loss — approximately 25-40% of total weight lost may be lean tissue. This is why resistance training and adequate protein intake (1.0-1.2g/kg) are strongly recommended alongside GLP-1 therapy. GH secretagogues may better preserve muscle mass, but the evidence is less robust.
How long do fat loss peptides take to work?
GLP-1 agonists typically show noticeable weight loss within 4-8 weeks of reaching therapeutic doses. Maximum weight loss plateaus around 52-72 weeks. GH secretagogues may take 8-12 weeks for body composition changes to become apparent.